Yr Athro Awen Gallimore

2021

• Teijeira Crespo, A.et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
• Lauder, S. N., Vanhaesebroeck, B. and Gallimore, A. 2021. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach. British Journal of Cancer 125, pp. 467-469. (10.1038/s41416-021-01285-1)
• Codd, A. S.et al. 2021. Neutrophilia, lymphopenia and myeloid dysfunction: A living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology (10.1093/oxfimm/iqab016)
• Thomson, A.et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124, pp. 1552-1555. (10.1038/s41416-021-01283-3)
• Milutinovic, S.et al. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7(3), pp. 214-225. (10.1016/j.trecan.2020.10.001)
• MacLachlan, B. J.et al. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51(2), pp. 331-341. (10.1002/eji.202048753)
• Lauder, S. N.et al. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology., Vol. 163. Elsevier, pp. 59-75., (10.1016/bs.mcb.2020.09.007)

2020

• Pires, A.et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8(12), pp. 1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
• Hanna, S. J.et al. 2020. T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology 2(1) (10.1093/oxfimm/iqaa007)
• Hughes, E.et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69, pp. 2063 - 2073. (10.1007/s00262-020-02603-x)
• Lauder, S. N.et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)
• Greenshields-Watson, A.et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32(2), article number: 107885. (10.1016/j.celrep.2020.107885)
• Scurr, M. J.et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)

2019

• MacLachlan, B. J.et al. 2019. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry 294(52), pp. 20246-20258. (10.1074/jbc.RA119.009437)
• Appanna, G. D.et al. 2019. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM: An International Journal of Medicine 112(10), pp. 793-795. (10.1093/qjmed/hcz161)
• Gallimore, A., Quezada, S. A. and Roychoudhuri, R. 2019. Regulatory T cells in cancer: where are we now?. Immunology 157(3), pp. 187-189. (10.1111/imm.13088)
• Thomson, A.et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19, article number: 98. (10.1186/s12876-019-1002-4)
• Watson, H. A.et al. 2019. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Frontiers in Immunology 10, article number: 1321. (10.3389/fimmu.2019.01321)
• Besneux, M.et al. 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68, pp. 247-256. (10.1007/s00262-018-2266-1)

2018

• Jones, E., Gallimore, A. and Ager, A. 2018. Defining high endothelial venules and tertiary lymphoid structures in cancer. In: Tertiary Lymphoid Structures. Methods in Molecular Biology., Vol. 1845. Methods in Molecular Biology Humana Press, pp. 99-118., (10.1007/978-1-4939-8709-2_7)
• May, S.et al. 2018. Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. Journal of Pathology 245(3), pp. 270-282. (10.1002/path.5074)
• Hill, D.et al. 2018. Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. International Journal of Cancer 143(1), pp. 167-178. (10.1002/ijc.31298)
• Hughes, E.et al. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154(1), pp. 62-68. (10.1111/imm.12913)
• Miles, J. J.et al. 2018. Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation 128(4), pp. 1569-1580. (10.1172/JCI91512)

2017

• Colbeck, E. J.et al. 2017. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?. Frontiers in Immunology 8, article number: 1830. (10.3389/fimmu.2017.01830)
• Colbeck, E. J.et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)
• Scurr, M.et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3(10), article number: e172579. (10.1001/jamaoncol.2017.2579)
• Scurr, M. J.et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research, article number: clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
• Chen, H.et al. 2017. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells. Immunology and Cell Biology 95(7), pp. 620-629. (10.1038/icb.2017.21)
• Scurr, M.et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35(7), pp. 154-154. (10.1200/JCO.2017.35.7_suppl.154)

2016

• Hughes, E.et al. 2016. Treating metastatic disease through manipulation of regulatory T cells. European Journal of Immunology 46, pp. 578-578., article number: 827. (10.1002/eji.201670200)

2015

• Colbeck, E.et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6(28), pp. 24649-24659. (10.18632/oncotarget.5584)
• Pembroke, T., Gallimore, A. M. and Godkin, A. J. 2015. Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods 424, pp. 131-135. (10.1016/j.jim.2015.04.011)
• Ondondo, B.et al. 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145(1), pp. 94-104. (10.1111/imm.12430)
• Scurr, M. J.et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107(4), article number: djv001. (10.1093/jnci/djv001)
• Costa Bento, D. F.et al. 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4(3), pp. 653-660., article number: e974374. (10.4161/2162402X.2014.974374)
• Ford, C. A.et al. 2015. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology 25(5), pp. 577-588. (10.1016/j.cub.2014.12.059)
• Stack, G.et al. 2015. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathogens 11(2), article number: e1004641. (10.1371/journal.ppat.1004641)

2014

• Ondondo, B.et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134(9), pp. 2156-2167. (10.1002/ijc.28556)
• Stacey, M. A.et al. 2014. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. Cell Host and Microbe 15(4), pp. 471-483. (10.1016/j.chom.2014.03.003)

2013

• Scurr, M.et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1(6), article number: 416. (10.1158/2326-6066.CIR-13-0035)
• Lauder, S. N.et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
• Scurr, M. J.et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
• Ondondo, B.et al. 2013. Home sweet home: The tumor microenvironment as a haven for regulatory T cells. Frontiers in Immunology 4, article number: 197. (10.3389/fimmu.2013.00197)
• Pembroke, T., Gallimore, A. and Godkin, A. 2013. Flow cytometry makes all the difference. Journal of Hepatology 59(4), pp. 909-910. (10.1016/j.jhep.2013.05.047)
• Pembroke, T.et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
• Pembroke, T., Gallimore, A. and Godkin, A. 2013. Rapid innate control of antigen abrogates adaptive immunity. Immunology 138(4), pp. 293-297. (10.1111/imm.12048)
• Gallimore, A. M. and Godkin, A. J. 2013. Epithelial barriers, microbiota, and colorectal cancer. New England Journal of Medicine 368(3), pp. 282-284. (10.1056/NEJMcibr1212341)

2012

• Humphreys, I. R.et al. 2012. Avidity of influenza-specific memory CD8+T-cell populations decays over time compromising antiviral immunity. European Journal of Immunology 42(12), pp. 3235-3242. (10.1002/eji.201242575)
• Hindley, J. P.et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72(21), pp. 5473-5482. (10.1158/0008-5472.CAN-12-1912)
• Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279(1), pp. 21-24. (10.1016/j.cellimm.2012.08.004)
• Pembroke, T.et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
• Twohig, J. P.et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26(8), pp. 3575-3586. (10.1096/fj.11-200618)
• Kempshall, E.et al. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunology and Cell Biology 90(9), pp. 869-871. (10.1038/icb.2012.30)
• Pembroke, T.et al. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61(S2), pp. A144-A145. (10.1136/gutjnl-2012-302514b.174)
• Scurr, M. J., Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61(S2), article number: A109. (10.1136/gutjnl-2012-302514b.88)
• Cole, D.et al. 2012. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications 3, article number: 665. (10.1038/ncomms1665)
• Betts, G. J.et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8), pp. 1163-1171. (10.1136/gutjnl-2011-300970)

2011

• Clement, M.et al. 2011. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. The Journal of Immunology 187(2), pp. 654-663. (10.4049/jimmunol.1003941)
• Lauder, S. N.et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)
• Hindley, J. P.et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research 71(3), pp. 736-746. (10.1158/0008-5472.CAN-10-1797)
• Ruge, F.et al. 2011. Delineating immune-mediated mechanisms underlying hair follicle destruction in the mouse mutant defolliculated. Journal of Investigative Dermatology 131(3), pp. 572-579. (10.1038/jid.2010.379)
• Godkin, A. J. and Gallimore, A. M. 2011. Setting the threshold for extra-thymic differentiation of Foxp3+ Tregs: TGF-β-dependent and T-cell autonomous. European Journal of Immunology 41(5), pp. 1218-1220. (10.1002/eji.201141576)

2010

• Lauder, S. N.et al. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
• Cuff, S.et al. 2010. Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells. The Journal of Immunology 184(2), pp. 607-614. (10.4049/jimmunol.0804089)
• Richards, H. C.et al. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131(4), pp. 583-592. (10.1111/j.1365-2567.2010.03333.x)

2009

• Gallagher, K. M. E.et al. 2009. Type I interferon (IFNα) acts directly on human memory CD4+ T cells altering their response to antigen. The Journal of Immunology 183(5), pp. 2915-2920. (10.4049/jimmunol.0801607)
• Baalasubramanian, S.et al. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182(9), pp. 5203-5207. (10.4049/jimmunol.0804243)

2008

• Jones, G. W.et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
• Morton, J.et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
• Longhi, M. P.et al. 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4(2), article number: e1000006. (10.1371/journal.ppat.1000006)
• Richards, H. C.et al. 2008. CD62L (L-Selectin) down-regulation does not affect memory T cell distribution but failure to shed compromises anti-viral immunity. Journal of Immunology 180(1), pp. 198-206.
• Gallimore, A. M. and Simon, A. K. 2008. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27(45), pp. 5886-5893. (10.1038/onc.2008.269)

2007

• Boulter, J. M.et al. 2007. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology 37(3), pp. 798-806. (10.1002/eji.200636743)
• Simon, A. K.et al. 2007. Regulatory T cells inhibit Fas ligand induced innate and adaptive tumour immunity. European Journal of Immunology 37(3), pp. 758-767. (10.1002/eji.200636593)
• Gallimore, A. M. and Godkin, A. J. 2007. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123(2), pp. 157-163. (10.1111/j.1365-2567.2007.02748.x)
• Betts, G.et al. 2007. The impact of regulatory T cells on carcinogen-induced sarcogenesis. British Journal of Cancer 96(12), pp. 1849-1854. (10.1038/sj.bjc.6603824)
• Betts, G. J., Godkin, A. J. and Gallimore, A. M. 2007. Reply: forkhead box P3-positive regulatory T cells in immune surveillance and cancer. British Journal of Cancer 97, pp. 1017-1018. (10.1038/sj.bjc.6603940)

2006

• Wise, M. P., Gallimore, A. M. and Godkin, A. J. 2006. T-Cell costimulation [Letter]. New England Journal of Medicine 355(24), pp. 2594-2595. (10.1056/NEJMc062767)
• Betts, G. J.et al. 2006. Regulating the immune response to tumours. Advanced Drug Delivery Reviews 58(8), pp. 948-961. (10.1016/j.addr.2006.05.006)

2005

• Longhi, M. P.et al. 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175(11), pp. 7098-7102.
• Richards, H. E.et al. 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116(s1), pp. 36-36. (10.1111/j.1365-2567.2005.02287.x)
• Clarke, S. L.et al. 2005. Analysis of CD4(+)CD25(hi) cells in peripheral blood and lymph nodes of patients with colorectal cancer. Immunology 116(1), pp. 37-37. (10.1111/j.1365-2567.2005.02287.x)

2003

• Jones, E.et al. 2003. The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology 109(1), pp. 68-75. (10.1046/j.1365-2567.2003.01636.x)

2002

• Simon, A. K.et al. 2002. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2(4), pp. 315-322. (10.1016/S1535-6108(02)00151-4)
• Golgher, D.et al. 2002. CD25+ regulatory cells uncover immune responses to shared tumour rejection antigens. European Journal of Immunology 32(11), pp. 3267-3275. (10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1)

1999

• Bachmann, M. F.et al. 1999. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. Journal of Experimental Medicine 189(10), pp. 1521-1530.

1998

• Gallimore, A. M.et al. 1998. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology 28(10), pp. 3301-3311.
• Gallimore, A. M., Hengartner, H. and Zinkernagel, R. 1998. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunological Reviews 164, pp. 29-36. (10.1111/j.1600-065X.1998.tb01205.x)
• Gallimore, A. M.et al. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Molecular Immunology 35(10), pp. 581-591.
• Gallimore, A. M.et al. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. Journal of Experimental Medicine 187(10), pp. 1647-1657.

1996

• Gotch, F., Gallimore, A. M. and McMichael, A. 1996. Cytotoxic T cells--protection from disease progression--protection from infection. Immunology Letters 51(1-2), pp. 125-128. (10.1016/0165-2478(96)02566-7)

1995

• Gallimore, A. M.et al. 1995. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Natural Medicines 1(11), pp. 1167-1173.
• Boyson, J. E.et al. 1995. The MHC E locus in macaques is polymorphic and is conserved between macaques and humans. Immunogenetics 41(2-3), pp. 59-68. (10.1007/BF00182314)
• Rowland-Jones, S.et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Natural Medicines 1(1), pp. 59-64.

1993

• Gotch, F.et al. 1993. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. The Journal of Immunology 151(6), pp. 3361-3369.